12,798 Becton, Dickinson and Company $BDX Shares Acquired by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 18.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 80,374 shares of the medical instruments supplier’s stock after buying an additional 12,798 shares during the period. Nisa Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $14,387,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in BDX. Maryland Capital Advisors Inc. lifted its stake in Becton, Dickinson and Company by 13,900.0% in the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 139 shares during the last quarter. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at approximately $26,000. Meeder Asset Management Inc. increased its position in shares of Becton, Dickinson and Company by 152.2% in the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD purchased a new stake in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $29,000. Finally, Bell Investment Advisors Inc acquired a new stake in shares of Becton, Dickinson and Company in the 2nd quarter valued at $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $194.29 on Thursday. The company has a market capitalization of $53.53 billion, a price-to-earnings ratio of 58.52, a price-to-earnings-growth ratio of 13.07 and a beta of 0.21. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $195.99. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a 50 day moving average price of $184.73 and a 200 day moving average price of $164.54.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same quarter last year, the company earned $3.68 earnings per share. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were issued a $1.05 dividend. The ex-dividend date was Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio is presently 126.51%.

Insider Activity at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 6,906 shares of company stock valued at $1,265,855 in the last ninety days. Insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

BDX has been the subject of several recent analyst reports. Barclays started coverage on shares of Becton, Dickinson and Company in a research report on Wednesday, October 7th. They set an “underweight” rating and a $165.00 price objective for the company. Royal Bank Of Canada increased their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a report on Thursday, August 13th. TD Cowen increased their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. UBS Group initiated coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price target on the stock. Finally, Evercore set a $180.00 price target on Becton, Dickinson and Company in a report on Monday, July 6th. Eight research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $185.07.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.